Abstract P056: MHC CLass II-associated Invariant Peptide (CLIP) Antagonism During Chronic Lipopolysaccharide Treatment Preserves Afferent Arteriolar Autoregulatory Behavior
Lipopolysaccharide (LPS) is a cell wall component of gram-negative bacteria that can activate toll-like receptor 4, which in turn, activates the innate immune system. Chronic immune system activation is linked to blunted afferent arteriolar autoregulatory behavior and kidney injury. MHC Class II-associated invariant peptide (CLIP) provides a critical step in antigen processing, presentation, and adaptive immune system activation. Accordingly, we postulated that treatment with a competitive CLIP antagonist (CAP) during chronic low-dose LPS exposure would preserve afferent arteriolar autoregulatory behavior. Rats were implanted with osmotic minipumps (day 0) for infusion of LPS (0.01mg/kg/day) or saline (0.9% NaCl; 0.5μl/hr) for 8 days and then the kidneys were harvested for juxtamedullary nephron studies. Four groups (n=6/group) were studied: Control, LPS, LPS + CAP and Sham + CAP. Both LPS + CAP and Sham + CAP groups were treated with CAP (3mg/kg/day; i.p.) on days 1-7. Autoregulatory behavior was assessed in these groups by increasing perfusion pressure in 15 mmHg increments from 65 to 170 mmHg. Starting baseline diameters were similar across the control (15.2 ± 1.2 μm), LPS (14.1 ± 1.0 μm), LPS + CAP (15.1 ± 1.0), and Sham + CAP (15.7 ± 0.6) groups. When perfusion pressure was increased from 65 to 170 mmHg, control and sham + CAP afferent arteriolar diameter decreased significantly by 26 ± 4% and 25 ± 2% (P<0.05), respectively. In contrast, afferent diameters from LPS treated kidneys decreased by just 5 ± 2% over the same pressure range indicating impaired afferent arteriolar autoregulatory behavior. In LPS + CAP treated kidneys, afferent arteriolar diameter decreased by 17 ± 2% (P<0.05) over the same pressure range signifying preservation of autoregulatory behavior. These data support the hypothesis that CLIP antagonism during chronic low dose LPS treatment preserves afferent arteriolar autoregulatory behavior. Inhibiting CLIP may open novel therapeutic targets for inflammatory kidney disease.
Author Disclosures: J. Van Beusecum: B. Research Grant (includes principal investigator, collaborator, or consultant and pending grants as well as grants already received); Modest; HL098135. B. Research Grant (includes principal investigator, collaborator, or consultant and pending grants as well as grants already received); Significant; 14PRE20460061. C. Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support); Significant; CLIP antagonist from VG Lifesciences. A.K. Cook: None. S. Zhang: None. R.P. Tobin: A. Employment; Modest; Assistant Scientific Advisor- VG Life Sciences. M.K. Newell-Rogers: A. Employment; Significant; Chief Scientist- VG Life Sciences. E.W. Inscho: B. Research Grant (includes principal investigator, collaborator, or consultant and pending grants as well as grants already received); Significant; HL098135. C. Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support); Significant; CLIP antagonist from VG Lifesciences.
- © 2015 by American Heart Association, Inc.